Our syngeneic mouse PTCL xenograft model demonstrated that alisertib as a single agent had a TGI of ∼30% that significantly improved TGI to >90% when combined with an anti-PD-L1 monoclonal antibody which had no single agent activity. This evidence concerns the gene CD274 and mature T-cell and NK-cell non-Hodgkin lymphoma.